Literature DB >> 16250663

Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.

Heiko Ullmann1, Sabine Meis, Darunee Hongwiset, Claudia Marzian, Michael Wiese, Peter Nickel, Didier Communi, Jean-Marie Boeynaems, Christian Wolf, Ralf Hausmann, Günther Schmalzing, Matthias U Kassack.   

Abstract

Selective and potent P2Y(11) receptor antagonists have yet to be developed, thus impeding an evaluation of this G protein-coupled receptor mainly expressed on immune cells. Taking suramin with moderate inhibitory potency as a template, 18 ureas with variations of the methyl groups of suramin and their precursors were functionally tested at P2Y(11), P2Y(1), and P2Y(2) receptors. Fluorine substitution of the methyl groups of suramin led to the first nanomolar P2Y(11) antagonist (8f, NF157, pK(i): 7.35). For selectivity, 8f was also tested at various P2X receptors. 8f displayed selectivity for P2Y(11) over P2Y(1) (>650-fold), P2Y(2) (>650-fold), P2X(2) (3-fold), P2X(3) (8-fold), P2X(4) (>22-fold), and P2X(7) (>67-fold) but no selectivity over P2X(1). QSAR studies confirm that residues with favored resonance and size parameters in the aromatic linker region can indeed lead to an increased potency as is the case for 8f. A symmetric structure linking two anionic clusters seems to be required for bioactivity. 8f may be helpful for studies evaluating the physiological role of P2Y(11) receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16250663     DOI: 10.1021/jm050301p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

2.  Purine receptors and Ca(2+) signalling in the human blood-brain barrier endothelial cell line hCMEC/D3.

Authors:  Willem Bintig; Daniela Begandt; Barbara Schlingmann; Linda Gerhard; Maria Pangalos; Lutz Dreyer; Natalija Hohnjec; Pierre-Olivier Couraud; Ignacio A Romero; Babette B Weksler; Anaclet Ngezahayo
Journal:  Purinergic Signal       Date:  2011-09-29       Impact factor: 3.765

3.  Identification of Rift Valley fever virus nucleocapsid protein-RNA binding inhibitors using a high-throughput screening assay.

Authors:  Mary Ellenbecker; Jean-Marc Lanchy; J Stephen Lodmell
Journal:  J Biomol Screen       Date:  2012-05-29

Review 4.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 6.  P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.

Authors:  Gary A Weisman; Lucas T Woods; Laurie Erb; Cheikh I Seye
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-09       Impact factor: 4.388

Review 7.  A critical look at the function of the P2Y11 receptor.

Authors:  Karin Dreisig; Birgitte Rahbek Kornum
Journal:  Purinergic Signal       Date:  2016-05-31       Impact factor: 3.765

Review 8.  P2Y nucleotide receptors: promise of therapeutic applications.

Authors:  Kenneth A Jacobson; Jean-Marie Boeynaems
Journal:  Drug Discov Today       Date:  2010-06-02       Impact factor: 7.851

9.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Development of selective agonists and antagonists of P2Y receptors.

Authors:  Kenneth A Jacobson; Andrei A Ivanov; Sonia de Castro; T Kendall Harden; Hyojin Ko
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.